SLC6A1-AS1

Across TCGA pan-cancer cohorts, SLC6A1-AS1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of SLC6A1-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SLC6A1-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC6A1-AS1 is over-expressed in tumor, although a few such as HNSC and LUSC show the opposite, repressed pattern.

KIRC, HNSC, and LIHC are the cancer types where SLC6A1-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC6A1-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.500	<.001	10	view →
HNSC	All	II,III,IV	−0.133	<.001	10	view →
LIHC	All	All	+0.527	<.001	7	view →
LUSC	Female	All	−0.321	<.001	6	view →
BRCA	Female	II,III,IV	+0.100	.020	4	view →
KICH	All	IV	−0.157	.039	1	view →
LUAD	Male	III,IV	−0.138	.010	1	view →
STAD	All	III,IV	+0.097	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

SLC6A1-AS1–KIRC

Open the KIRC breakdown →